Is Sclerostin Level Associated with Cardiovascular Diseases in Hemodialysis Patients?

Area of Science:

• Nephrology
• Cardiology
• Endocrinology

Background:

• Sclerostin is implicated in bone and vascular health.
• Patients undergoing hemodialysis (HD) often exhibit altered sclerostin levels.
• Arterial stiffness is a significant predictor of cardiovascular events (CVE) in HD populations.

Purpose of the Study:

• To investigate the relationship between sclerostin levels, arterial stiffness (measured by pulse wave velocity, PWV), and the incidence of CVE in patients on hemodialysis.
• To identify factors associated with sclerostin levels in HD patients.

Main Methods:

• Cross-sectional study measuring sclerostin and PWV in 97 HD patients and 40 controls.
• Univariable and multivariable regression analyses were used to assess associations.
• Prospective observation for the occurrence of fatal or nonfatal CVEs.

Main Results:

• HD patients had significantly higher sclerostin levels compared to controls.
• Sclerostin positively correlated with age, male gender, cardiovascular disease, statin use, BMI, and PWV in univariable analysis.
• Multivariate analysis revealed positive associations of sclerostin with male gender and statin use, and a negative association with parathormone (PTH). A significant association between sclerostin and PWV was not found in multivariate analysis, despite a univariate correlation.

Conclusions:

• Sclerostin levels are elevated in hemodialysis patients.
• The relationship between sclerostin and arterial stiffness (PWV) in HD patients requires further investigation.
• Understanding sclerostin's role may offer insights into managing cardiovascular risk in HD patients.